Zentalis Pharmaceuticals Future Growth
Future criteria checks 2/6
Zentalis Pharmaceuticals is forecast to grow earnings and revenue by 5.3% and 47.8% per annum respectively. EPS is expected to grow by 14.9% per annum. Return on equity is forecast to be -106.9% in 3 years.
Key information
5.3%
Earnings growth rate
14.9%
EPS growth rate
Biotechs earnings growth | 25.1% |
Revenue growth rate | 47.8% |
Future return on equity | -106.9% |
Analyst coverage | Good |
Last updated | 17 May 2024 |
Recent future growth updates
Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit
May 09Recent updates
Results: Zentalis Pharmaceuticals, Inc. Confounded Analyst Expectations With A Surprise Profit
May 09Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Apr 12We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Feb 29Zentalis: Leading WEE1 Developer After AstraZeneca's Exit
Feb 05Is Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Trading At A 45% Discount?
Jan 09We're Not Very Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate
Oct 13We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
Jun 30We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Mar 17We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Dec 01Zentalis Pharmaceuticals promotes co-founder Kevin Bunker to chief scientific officer
Sep 27Zentalis Pharmaceuticals has a new chief medical officer
Sep 19Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans
Aug 17Here's Why We're Not Too Worried About Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation
May 02We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Jan 12We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
Oct 14Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jul 02Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Mar 08Companies Like Zentalis Pharmaceuticals (NASDAQ:ZNTL) Are In A Position To Invest In Growth
Jan 20Zentalis initiates multiple early-stage clinical trials for cancer
Jan 06Have Insiders Sold Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Recently?
Nov 28Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 73 | -286 | -271 | -305 | 8 |
12/31/2025 | 3 | -306 | -287 | -253 | 8 |
12/31/2024 | 32 | -197 | -232 | -198 | 10 |
3/31/2024 | 41 | -219 | -211 | -211 | N/A |
12/31/2023 | N/A | -292 | -208 | -208 | N/A |
9/30/2023 | N/A | -286 | -205 | -205 | N/A |
6/30/2023 | N/A | -285 | -201 | -199 | N/A |
3/31/2023 | N/A | -241 | -165 | -163 | N/A |
12/31/2022 | N/A | -237 | -166 | -164 | N/A |
9/30/2022 | N/A | -232 | -168 | -163 | N/A |
6/30/2022 | N/A | -182 | -169 | -164 | N/A |
3/31/2022 | N/A | -168 | -173 | -167 | N/A |
12/31/2021 | N/A | -159 | -160 | -154 | N/A |
9/30/2021 | N/A | -149 | -149 | -144 | N/A |
6/30/2021 | N/A | -179 | -133 | -132 | N/A |
3/31/2021 | N/A | -152 | -109 | -107 | N/A |
12/31/2020 | N/A | -118 | -88 | -87 | N/A |
9/30/2020 | N/A | -92 | -73 | -73 | N/A |
6/30/2020 | N/A | -70 | -62 | -62 | N/A |
3/31/2020 | N/A | -53 | -47 | -47 | N/A |
12/31/2019 | N/A | -46 | -39 | -39 | N/A |
12/31/2018 | 0 | -23 | -24 | -24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZNTL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ZNTL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ZNTL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ZNTL's revenue (47.8% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: ZNTL's revenue (47.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZNTL is forecast to be unprofitable in 3 years.